Trends in the consumption of attention deficit hyperactivity disorder medications in Castilla y León (Spain): Changes in the consumption pattern following the introduction of extended release methylphenidate

Pharmacoepidemiology and Drug Safety

Volumn 21, Issue 4, 2012, Pages 435-441

  Treceño, Carlos ^a   Martín Arias, Luis H ^a   Sáinz, Maria ^a   Salado, Inés ^a   García Ortega, Pilar ^a   Velasco, Veronica ^a   Jimeno, Natalia ^a   Escudero, Antonio ^a   Velasco, Alfonso ^a   Carvajal, Alfonso ^a  

^a UNIVERSITY OF VALLADOLID   (Spain)

Author keywords

Attention deficit hyperactivity disorder; Defined daily doses; Drug utilisation study; Methylphenidate; Stimulants

Indexed keywords

METHYLPHENIDATE;

ARTICLE; ATTENTION DEFICIT DISORDER; DRUG COST; DRUG FORMULATION; DRUG MARKETING; DRUG UTILIZATION; HUMAN; PHARMACY; PRIORITY JOURNAL; SPAIN;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; CHILD, PRESCHOOL; DATABASES, FACTUAL; DELAYED-ACTION PREPARATIONS; DRUG COSTS; HUMANS; METHYLPHENIDATE; MODELS, THEORETICAL; PHYSICIAN'S PRACTICE PATTERNS; SPAIN;

EID: 84859722275     PISSN: 10538569     EISSN: 10991557     Source Type: Journal    
DOI: 10.1002/pds.2348     Document Type: Article

References (45)

1. Polanczyk G, de Lima MS, Horta BL, Biederman J, Rohde LA. The worldwide prevalence of ADHD: a systematic review and metaregression analysis. Am J Psychiatry 2007; 164: 942-948.
2. Accessed, May 2011.
3. NICE clinical guideline. Attention deficit hyperactivity disorder. Diagnosis and management. NICE: London, 2008. Accessed, May 2011).
4. Williams NM, Zaharieva I, Martin A, et al. Rare chromosomal deletions and duplications in attention-deficit hyperactivity disorder: a genome-wide analysis. Lancet 2010; 376: 1401-1408.
5. Faraone SV, Buitelaar J. Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 2010; 19: 353-364.
6. Agencia Española de Medicamentos y Productos Sanitarios. Accessed, May 2011.
7. Zito JM, Safer DJ, dosReis S, Gardner JF, Boles M, Lynch F. Trends in the prescribing of psychotropic medications to preschoolers. JAMA 2000; 283: 1025-1030.
8. Olfson M, Gameroff MJ, Marcus SC, Jensen PS. National trends in the treatment of attention deficit hyperactivity disorder. Am J Psychiatry 2003; 160: 1071-1077.
9. Criado Alvarez JJ, Romo Barrientos C. Variability and tendencies in the consumption of methylphenidate in Spain. An estimation of the prevalence of attention deficit hyperactivity disorder. Rev Neurol 2003; 37: 806-810. [Spanish].
10. Castle L, Aubert RE, Verbrugge RR, Khalid M, Epstein RS. Trends in medication treatment for ADHD. J Atten Disord 2007; 10: 335-342.
11. Knellwolf AL, Deligne J, Chiarotti F, et al. Prevalence and patterns of methylphenidate use in French children and adolescents. Eur J Clin Pharmacol 2008; 64: 311-317.
12. Winterstein AG, Gerhard T, Shuster J, Zito J, Johnson M, Liu H. Saidi A. Utilization of pharmacologic treatment in youths with attention deficit/hyperactivity disorder in Medicaid database. Ann Pharmacother 2008; 42: 24-31.
13. Danish Medicines Agency.
14. Norwegian Institute of Public Health.
15. Hollingworth SA, Nissen LM, Stathis SS, Siskind DJ, Varghese JM, Scott JG. Australian national trends in stimulant dispensing: 2002-2009. Aust N Z J Psychiatry 2011; 45: 332-336.12.
16. Schubert I, Köster I, Lehmkuhl G The changing prevalence of attention-deficit/hyperactivity disorder and methylphenidate prescriptions: a study of data from a random sample of insurees of the AOK Health Insurance Company in the German State of Hesse, 2000-2007. Dtsch Arztebl Int 2010; 107: 615-621.
17. National Statistics Institute. Population in Spain.
18. Lunde PKM, Baksaas I, Halse M, Strommes B, Aeydvin K. The methodology of drug utilization studies. In Studies in drug utilization. Bergman U, Grimsson A, Wahba AHW, Werterholm B (eds). WHO Regional Office for Europe: Copenhagen, 1979; pp. 17-28.
19. WHO Collaborating Centre for Drug Statistics Methodology. Complete ATC index 2007:.
20. Stafford N. Bremen doctors sign up to reduce drug use in ADHD patients. BMJ 2011; 342: d127.
21. Accessed, Sep 2011.
22. Phillips CB. Medicine goes to school: teachers as sickness brokers for ADHD. PLoS Med 2006; 3:e182.
23. Castells X, Ramos-Quiroga JA, Rigau D, et al. Efficacy of methylphenidate for adults with attention-deficit hyperactivity disorder: a meta-regression analysis. CNS Drugs 2011; 25: 157-169.
24. Peterson K, McDonagh MS, Fu R. Comparative benefits and harms of competing medications for adults with attention-deficit hyperactivity disorder: a systematic review and indirect comparison meta-analysis. Psychopharmacology 2008; 197: 1-11.
25. Marcus SC, Wan GJ, Kemner JE, Olfson M. Continuity of methylphenidate treatment for attention-deficit/hyperactivity disorder. Arch Pediatr Adolesc Med 2005; 159: 572-578.
26. Asherson P, Adamou M, Bolea B, et al. Is ADHD a valid diagnosis in adults? Yes. BMJ 2010; 340: c549.
27. Moncrieff J, Timimi S. Is ADHD a valid diagnosis in adults? No. BMJ 2010; 340: c547.
28. Aragonès E, Piñol JL, Ramos-Quiroga JA, López-Cortacans G, Caballero A Bosch R. Prevalencia del déficit de atención e hiperactividad en personas adultas según el registro de las historias clínicas informatizadas en atención primaria. Rev Esp Salud Publica 2010; 84: 415-420.
29. Longstreth WT Jr, Koepsell TD, Ton TG, Hendrickson AF, van Belle G. The epidemiology of narcolepsy. Sleep 2007; 30: 13-26.
30. Enhancing, not cheating. Nature 2007; 450: 320.
31. Provigil (modafinil). In: 2006 Physicians' Desk Reference. 60th ed., Thompson PDR: Montvale, NJ; 2006: 1002-1007.
32. Kruszewski SP, Klotz SG. Modafinil: mischaracterization. J Clin Psychiatry 2007; 68: 970-971;.
33. Kruszewski SP. Euphorigenic and abusive properties of modafinil. Am J Psychiatry 2006; 163:549.
34. Accessed, May 2011.
35. Nissen SE. ADHD drugs and cardiovascular risk. N Engl J Med 2006; 354: 1445-1448.
36. Kroutil LA, Van Brunt DL, Herman-Stahl MA, Heller DC, Bray RM, Penne MA. Nonmedical use of prescription stimulants in the United States. Drug Alcohol Depend 2006; 84: 135-143.
37. Novak SP, Kroutil LA, Williams RL, Van Brunt DL. The nonmedical use of prescription ADHD medications: results from a national Internet panel. Subst Abuse Treat Prev Policy 2007; 2: 32.
38. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry 2009; 166: 992-1001.
39. Michelson D, Allen AJ, Busner J, et al. Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: a randomized, placebo-controlled study. Am J Psychiatry 2002; 159: 1896-1901.
40. Newcorn JH, Kratochvil CJ, Allen AJ, et al. Atomoxetine/Methylphenidate Comparative Study Group. Atomoxetine and osmotically released methylphenidate for the treatment of attention deficit hyperactivity disorder: acute comparison and differential response. Am J Psychiatry 2008; 165:721-730.
41. Garnock-Jones KP, Keating GM. Atomoxetine: a review of its use in attention-deficit hyperactivity disorder in children and adolescents. Paediatr Drugs 2009; 11:203-226.
42. Garnock-Jones KP, Keating GM. Spotlight on atomoxetine in attention-deficit hyperactivity disorder in children and adolescents. CNS Drugs 2010; 24: 85-88.
43. Dell'Agnello G, Zuddas A, Masi G, Curatolo P, Besana D, Rossi A. Use of atomoxetine in patients with attention-deficit hyperactivity disorder and co-morbid conditions. CNS Drugs. 2009; 23: 739-753.
44. Angold A, Erkanli A, Costello EJ. Stimulant treatment for children: A Community Perspective. J Am Acad Child Adolesc Psychiatry. 2000; 39: 975-984.
45. Accessed, Sep 2011.